Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05071833
Other study ID # Peppermint oil cardiometabolic
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 1, 2021
Est. completion date November 5, 2022

Study information

Verified date March 2023
Source University of Central Lancashire
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. Previous non-randomized interventions have shown that oral peppermint may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention. Therefore, the primary purpose of the proposed investigation is to test the ability of oral peppermint oil supplementation to improve cardiometabolic parameters in healthy individuals.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date November 5, 2022
Est. primary completion date August 15, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Healthy - Between 18 & 65 years - Non-smoker - BMI < 30 - Able to give informed consent Exclusion Criteria: - Pregnancy - Diabetes or any other metabolic/ uncontrolled hypertensive conditions - Food allergies to peppermint - Habitual consumption of peppermint - Not regularly taking medication or antioxidant supplements

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Peppermint oil.
Peppermint oil.
Other:
Placebo
Placebo

Locations

Country Name City State
United Kingdom Jonathan Sinclair Preston Lancashire

Sponsors (1)

Lead Sponsor Collaborator
University of Central Lancashire

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Systolic blood pressure Systolic blood pressure - measured using a digital blood pressure monitor Baseline
Primary Systolic blood pressure Systolic blood pressure - measured using a digital blood pressure monitor 20 days
Secondary Percent bodyfat Participants percentage composition of fat - measured using bio-electrical impedance Baseline
Secondary Percent bodyfat Participants percentage composition of fat - measured using bio-electrical impedance 20 days
Secondary Waist to hip ratio Ratio of waist to hip circumference - measured using anthropocentric tape 20 days
Secondary Waist to hip ratio Ratio of waist to hip circumference - measured using anthropocentric tape Baseline
Secondary Resting metabolic rate Estimated daily calorie usage (Kcal) at rest - obtained using a metabolic cart through indirect calorimetry. Baseline
Secondary Resting metabolic rate Estimated daily calorie usage (Kcal) at rest - obtained using a metabolic cart through indirect calorimetry. 20 days
Secondary Resting utilization of carbohydrates Percent contribution of carbohydrate to daily calories - at rest - obtained using a metabolic cart through indirect calorimetry. 20 days
Secondary Resting utilization of carbohydrates Percent contribution of carbohydrate to daily calories - at rest - obtained using a metabolic cart through indirect calorimetry. Baseline
Secondary Resting utilization of fats Percent contribution of fats to daily calories - at rest - obtained using a metabolic cart through indirect calorimetry. Baseline
Secondary Resting utilization of fats Percent contribution of fats to daily calories - at rest - obtained using a metabolic cart through indirect calorimetry. 20 days
Secondary Blood glucose Capillary blood glucose - mmol/L Baseline
Secondary Blood glucose Capillary blood glucose - mmol/L 20 days
Secondary Triglyceride glucose index Calculated as the natural logarithm of (blood triglycerides x blood glucose) /2) Baseline
Secondary Triglyceride glucose index Calculated as the natural logarithm of (blood triglycerides x blood glucose) /2) 20 days
Secondary Blood triglycerides Capillary blood triglycerides - mmol/L Baseline
Secondary Blood triglycerides Capillary blood triglycerides - mmol/L 20 days
Secondary Blood cholesterol (Total, HDL & LDL) Capillary blood cholesterol - mmol/L Baseline
Secondary Blood cholesterol (Total, HDL & LDL) Capillary blood cholesterol - mmol/L 20 days
Secondary Blood haemoglobin Capillary blood haemoglobin - g/L Baseline
Secondary Blood haemoglobin Capillary blood haemoglobin - g/L 20 days
Secondary Coop-Wonka chart Psychological wellbeing - The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring system for each thus the chart has a maximum score of 30 which indicates the lowest possible psychological Wellbeing. Baseline
Secondary Beck Depression Inventory Psychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible. Baseline
Secondary Coop-Wonka chart Psychological wellbeing - The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring system for each thus the chart has a maximum score of 30 which indicates the lowest possible psychological Wellbeing. 20 days
Secondary Beck Depression Inventory Psychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible. 20 days
Secondary State Trait Anxiety Inventory Psychological wellbeing - the state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety. Baseline
Secondary State Trait Anxiety Inventory Psychological wellbeing - the state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety. 20 days
Secondary Insomnia Severity Index Sleep quality - The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia. The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28. 20 days
Secondary Insomnia Severity Index Sleep quality - The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia. The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28. Baseline
Secondary Pittsburgh Sleep Quality Index Sleep quality - The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality. Baseline
Secondary Pittsburgh Sleep Quality Index Sleep quality - The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality. 20 days
Secondary Epworth Sleepiness Scale Sleep quality - The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24. Baseline
Secondary Epworth Sleepiness Scale Sleep quality - The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24. 20 days
Secondary Diastolic blood pressure Systolic and diastolic blood pressure - measured using a digital blood pressure monitor Baseline
Secondary Diastolic blood pressure Systolic and diastolic blood pressure - measured using a digital blood pressure monitor 20 days
See also
  Status Clinical Trial Phase
Recruiting NCT05880758 - Impact of Yo-Yo Sleep on Cardiometabolic Health N/A
Active, not recruiting NCT05192590 - Establishing Clinical Utility Evidence for Chronic Disease Management Testing N/A
Completed NCT06058845 - Efficacy of Tamarindus Indica Fruit Juice in Optimizing Cardiometabolic Health of Patients Living With HIV N/A
Completed NCT05473026 - Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors N/A
Enrolling by invitation NCT06284772 - FINRISK 2002 Re-examination
Active, not recruiting NCT05309057 - Network Meta-analysis of Intermittent Fasting and Cardiometabolic Risk
Recruiting NCT05897073 - Time-Restricted Eating, Exercise and Cardiometabolic Health in Obesity N/A
Recruiting NCT06371937 - iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease
Recruiting NCT06003686 - Spinal Cord Injury Model Systems (SCIMS) - Education Module N/A
Recruiting NCT05775016 - Effects of Adding L-BAIBA to Exercising Adult Overweight and Obese Men and Women N/A
Recruiting NCT05350111 - CArdioMetabolic Prevention in Adolescents N/A
Completed NCT06158191 - Long-term Benefits of Abdominal Fat Loss in Abdominally Obese Dyslipidemic Patients (SYNERGIE Study) N/A
Recruiting NCT04801745 - Vegan Diet, Amla Fruits and Uric Acid N/A
Not yet recruiting NCT06230861 - Effects of Quercetin on Cardiometabolic Outcomes N/A
Active, not recruiting NCT05627570 - A Study Comparing the Health Effects of Two Diets Following UK Dietary Guidance in People Living With Overweight or Obesity N/A
Active, not recruiting NCT04784624 - Virtual Lifestyle Program Evaluation During Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Enrolling by invitation NCT05079529 - Development The Potentiality of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) From Mycelia Extract of Indonesia's Ganoderma Lucidum as Adjuvant Therapy in Patients With Cardiometabolic Syndrome Phase 2
Completed NCT04776629 - A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors Phase 2
Completed NCT06457711 - Blood Pressure and Cardiometabolic Risk (Diet-to-HTN) N/A
Completed NCT06008886 - Effect of a Vegan Diet Versus a Mediterranean Diet. Assessing Health Outcomes N/A